Literature DB >> 12491514

Is whole-brain irradiation necessary for primary central nervous system lymphoma? Patterns of recurrence after partial-brain irradiation.

Yuta Shibamoto1, Naofumi Hayabuchi, Jun-ichi Hiratsuka, Sunao Tokumaru, Hiroki Shirato, Mitsuharu Sougawa, Natsuo Oya, Yuji Uematsu, Masahiro Hiraoka.   

Abstract

BACKGROUND: Neurotoxicity after whole-brain irradiation remains a major problem in the treatment of primary central nervous system lymphoma (PCNSL). To clarify whether whole-brain radiation is necessary for PCNSL, the authors retrospectively analyzed the outcome of patients treated with partial-brain irradiation.
METHODS: A nationwide survey was performed regarding the treatment of PCNSL. Among 62 institutions surveyed, 7 were identified in which whole-brain irradiation was not necessarily employed. Questionnaires were sent to these institutions and 43 patients who had been treated using partial-brain fields since 1985 were collected. Thirty-two patients had solitary lesions and 11 had multiple lesions. Patterns of recurrence could be identified in 38 patients.
RESULTS: The cumulative in-field and out-field recurrence rates at 5 years were 57% and 49%, respectively. Of 14 out-field recurrences, 2 occurred at the safety margin of the previous radiation field. The out-field recurrence rate was 45% in patients with a single lesion and 67% in those with multiple tumors (P = 0.79). The out-field recurrence rate was 22% for patients treated with safety margins of > or = 4 cm and 83% for those treated with safety margins of < 4 cm (P = 0.0079). The median survival time and the 5-year survival rate were 28.5 months and 20%, respectively, in the former group of patients and 15 months and 11%, respectively, in the latter group (P = 0.057).
CONCLUSIONS: Focal radiotherapy with safety margins of < 4 cm appears to be associated with a very high rate of out-field recurrence, but the use of a radiation field with generous safety margins (> or = 4 cm) appears to be worth further investigation. Copyright 2003 American Cancer Society.

Entities:  

Mesh:

Year:  2003        PMID: 12491514     DOI: 10.1002/cncr.11035

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  26 in total

1.  Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma.

Authors:  Christian Grommes; James L Rubenstein; Lisa M DeAngelis; Andres J M Ferreri; Tracy T Batchelor
Journal:  Neuro Oncol       Date:  2019-02-19       Impact factor: 12.300

Review 2.  Advances in Primary Central Nervous System Lymphoma.

Authors:  Lauren B Patrick; Nimish A Mohile
Journal:  Curr Oncol Rep       Date:  2015-12       Impact factor: 5.075

Review 3.  Whither whole brain radiotherapy for primary CNS lymphoma?

Authors:  Lisa M DeAngelis
Journal:  Neuro Oncol       Date:  2014-07-10       Impact factor: 12.300

4.  Initial experiences of palliative stereotactic radiosurgery for recurrent brain lymphomas.

Authors:  Masato Sakamoto; Natsuo Oya; Takashi Mizowaki; Norio Araki; Yasushi Nagata; Kenji Takayama; Jun A Takahashi; Hideyuki Kano; Takahisa Katsuki; Nobuo Hashimioto; Masahiro Hiraoka
Journal:  J Neurooncol       Date:  2006-03       Impact factor: 4.130

5.  Results of primary central nervous system lymphoma treated by radiation and chemotherapy: retrospective analysis of twelve institutions in the Tokai District of Japan, 1995-1999.

Authors:  Toshiki Kawamura; Tsuneo Ishiguchi; Yuta Shibamoto; Hiroyuki Ogino; Shunichi Ishihara; Tetsuya Yamada; Kazuhiro Katada; Kazunori Suzuki; Hiromasa Suzuki; Mikio Mimura
Journal:  Radiat Med       Date:  2006-01

6.  Primary CNS lymphoma treated with radiotherapy in Japan: a survey of patients treated in 2005-2009 and a comparison with those treated in 1985-2004.

Authors:  Yuta Shibamoto; Minako Sumi; Shunsuke Onodera; Haruo Matsushita; Chikao Sugie; Yukihisa Tamaki; Hiroshi Onishi; Eisuke Abe; Masahiko Koizumi; Daisuke Miyawaki; Seiji Kubota; Etsuyo Ogo; Takuma Nomiya; Mitsuhiro Takemoto; Hideyuki Harada; Ippei Takahashi; Yoshio Ohmori; Naoya Ishibashi; Sunao Tokumaru; Kazunori Suzuki
Journal:  Int J Clin Oncol       Date:  2013-12-03       Impact factor: 3.402

Review 7.  Treatment of primary central nervous system lymphoma.

Authors:  Meltem Ekenel; Lisa M DeAngelis
Journal:  Curr Neurol Neurosci Rep       Date:  2007-05       Impact factor: 5.081

8.  A case series of primary central nervous system posttransplantation lymphoproliferative disorder: imaging and clinical characteristics.

Authors:  Wendell Lake; Julie E Chang; Tabassum Kennedy; Adam Morgan; Shahriar Salamat; Mustafa K Başkaya
Journal:  Neurosurgery       Date:  2013-06       Impact factor: 4.654

9.  Treatment of primary central nervous system lymphoma.

Authors:  Meltem Ekenel; Lisa M Deangelis
Journal:  Curr Treat Options Neurol       Date:  2007-07       Impact factor: 3.598

Review 10.  Management of elderly patients with primary central nervous system lymphoma.

Authors:  Mariza Daras; Lisa M DeAngelis
Journal:  Curr Neurol Neurosci Rep       Date:  2013-05       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.